GSK Reportedly To Lay Off 1,000 In China
This article was originally published in Scrip
Executive Summary
After a stormy year in China, GlaxoSmithKline has gone through major changes including the global transfer of its oncology assets to Novartis. But the underlying broader reasons for the company's newly reported layoffs in China could be more deep-rooted and far-reaching.